返回 Agendas
Session 2B: Non Clinical Track: miRNA
Session Chair(s)
Aimee L. Jackson, PHD
Chief Scientific Officer
Atalanta Therapeutics, United States
Renqin Duan, PHD
Toxicologist
FDA, United States
During this session the focus will be on major challenges associated with development of microRNA-based therapeutics, demonstration of PK/PD relationships, and validation of translational biomarkers to optimize clinical dosing. Nonclinical and clinical data addressing these challenges will be presented.
Speaker(s)
Development of microRNA-based Therapeutics
Aimee L. Jackson, PHD
Atalanta Therapeutics, United States
Chief Scientific Officer
Controversies with miRNA Development
John S. Grundy, PHD
Ionis Pharmaceuticals, Inc., United States
Vice President, DMPK & Toxicology
Delivery Challenges Facing Small and Large Nucleic Acid-based Therapeutics
Christopher Cheng, PHD
Verve Therapeutics, United States
Development Scientist II, Nucleric Acid Drug Formulations
Panel Discussion
All Session Speakers, United States